For Healthcare Professionals

Podcasts And Expert Series

Clot, Clot, Who's There?

Explore the world of thrombosis and hemostasis with "Clot Clot, Who's There?", a thought-provoking podcast brought to you by Vasculearn Network in collaboration with the Thrombosis and Haemostasis Editors (Thieme).

Explore the world of thrombosis and hemostasis with "Clot Clot, Who's There?", a thought-provoking podcast brought to you by Vasculearn Network in collaboration with the Thrombosis and Haemostasis Editors (Thieme).

Explore the world of thrombosis and hemostasis with "Clot Clot, Who's There?", a thought-provoking podcast brought to you by Vasculearn Network in collaboration with the Thrombosis and Haemostasis Editors (Thieme).

AF Gone, Clot Still Knocking?

Feb 9, 2026

What's Clotting in 2026

Jan 7, 2026

A Bridge Too Far? Navigating Perioperative Anticoagulation Challenges in Nonurgent Procedures

Dec 1, 2025

Smarter, Safer Antithrombotic Care: What Stewardship Really Means

Oct 30, 2025

Recent Advances in Immunothrombosis & Thromboinflammation

Sep 29, 2025

When Time is Limb: Acute Limb Ischemia and Thrombotic Emergencies

Aug 22, 2025

Conversations That Count: Communicating With Patients About Anticoagulation

Jun 24, 2025

Global Rhythm: US and European Atrial Fibrillation Guidelines Head-to-Head

May 28, 2025

Risky Business: Stratifying VTE and Managing Anticoagulation

Apr 25, 2025

Sex as a Risk Factor for AF-related Stroke

Feb 19, 2025

The Burden of Atrial Fibrillation

Jan 29, 2025

Cholesterol Conversations: Special Edition VLN Podcast

Cholesterol Conversations: Special Edition VLN Podcast

Cholesterol Conversations: Special Edition VLN Podcast

Statins are the first-line therapy for lowering LDL-C and reducing ASCVD risk, yet many high-risk patients remain undertreated. VLN’s Cholesterol Conversations podcast explores the latest ASCVD management guidance, treatment options for optimal LDL-C lowering, and emerging data on novel and combination therapies.

Statins are the first-line therapy for lowering LDL-C and reducing ASCVD risk, yet many high-risk patients remain undertreated. VLN’s Cholesterol Conversations podcast explores the latest ASCVD management guidance, treatment options for optimal LDL-C lowering, and emerging data on novel and combination therapies.

Statins are the first-line therapy for lowering LDL-C and reducing ASCVD risk, yet many high-risk patients remain undertreated. VLN’s Cholesterol Conversations podcast explores the latest ASCVD management guidance, treatment options for optimal LDL-C lowering, and emerging data on novel and combination therapies.

Follow Along & Subscribe to VLN's Channel:
Mastering LDL Management in 2025

Mar 30, 2025

Mastering LDL Management in 2025

Mar 30, 2025

Mastering LDL Management in 2025

Mar 30, 2025

How Do We Get There from Here: Partnering with Patients to Achieve LDL Goals

Mar 8, 2023

How Do We Get There from Here: Partnering with Patients to Achieve LDL Goals

Mar 8, 2023

How Do We Get There from Here: Partnering with Patients to Achieve LDL Goals

Mar 8, 2023

ASCVD Management: Making the Case for Nonstatin Therapies

Feb 21, 2023

ASCVD Management: Making the Case for Nonstatin Therapies

Feb 21, 2023

ASCVD Management: Making the Case for Nonstatin Therapies

Feb 21, 2023